Edifoligide: A transcription factor decoy to modulate smooth muscle cell proliferation in vein bypass

Cardiovascular Drug Reviews

Volumn 25, Issue 3, 2007, Pages 221-234

  Hoel, Andrew W ^a   Conte, Michael S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

E2F; Intimal hyperplasia; Oligonucleotides; Smooth muscle cells; Transcription factor decoy; Vein bypass graft

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; DOUBLE STRANDED DNA; EDIFOLIGIDE; OLIGONUCLEOTIDE; RECOMBINANT DNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F;

ARTERY INTIMA PROLIFERATION; BLOOD VESSEL SHUNT; BYPASS SURGERY; CELL CYCLE; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE COURSE; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; GENOMICS; GRAFT DYSFUNCTION; GRAFT FAILURE; HUMAN; HUMAN GENOME PROJECT; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REIMPLANTATION; REVIEW; RNA INTERFERENCE; SMOOTH MUSCLE FIBER; SURGICAL TECHNIQUE; TREATMENT OUTCOME; VASCULAR DISEASE; VEIN BYPASS;

ANIMALS; CELL PROLIFERATION; CORONARY ARTERY BYPASS; E2F TRANSCRIPTION FACTORS; GRAFT OCCLUSION, VASCULAR; HUMANS; MODELS, BIOLOGICAL; MUSCLE, SMOOTH, VASCULAR; OLIGONUCLEOTIDES;

EID: 35148859256     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2007.00020.x     Document Type: Review

References (37)

1. Alexander JH, Ferguson TB Jr., Joseph DM, Mack MJ, Wolf RK, Gibson CM, Gennevois D, Lorenz TJ, Harrington RA, Peterson ED, et al 2005a) The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: Study rationale, design, and baseline patient characteristics. Am Heart J 150 : 643 649.
2. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr., Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, et al 2005b) Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: A randomized controlled trial. JAMA 294 : 2446 2454.
3. Bielinska A, Schivdasani R, Zhang L (1990) Regulation of gene expression with double-stranded phosphothioate oligonucleotides. Science 250 : 997 1000.
4. Braun-Dullaeus RC, Mann MJ, Dzau VJ (1998) Cell cycle progression: New therapeutic target for vascular proliferative disease. Circulation 98 : 82 89.
5. Cam H, Dynlacht BD (2003) Emerging roles for E2F: Beyond the G1/S transition and DNA replication. Cancer Cell 3 : 311 316.
6. Chang MW, Barr E, Lu MM, Barton K, Leiden JM (1995) Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 96 : 2260 2268.
7. Colman A (1990) Antisense strategies in cell and developmental biology. J Cell Sci 97 : 399 409.
8. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ, Namini H, Hamdan AD, Roddy SP, Belkin M, et al 2006) Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg 43 : 742 751 discussion 751.
9. Conte MS, Belkin M, Upchurch GR, Mannick JA, Whittemore AD, Donaldson MC (2001) Impact of increasing comorbidity on infrainguinal reconstruction: A 20-year perspective. Ann Surg 233 : 445 452.
10. Conte MS, Mann MJ, Simosa HF, Rhynhart KK, Mulligan RC (2002) Genetic interventions for vein bypass graft disease: A review. J Vasc Surg 36 : 1040 1052.
11. Crooke ST (2000) Progress in antisense technology: The end of the beginning. Methods Enzymol 313 : 3 45.
12. Degregori J, Kowalik T, Nevins J (1995) Cellular targets for activation by the E2F1 transcription factor include DNA synthesis - and G1/S regulatory genes. Mol Cell Biol 15 : 4215 4224.
13. Degregori J, Leone G, Miron A, Jakoi L, Nevins J (1997) Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci USA 94 : 7245 7250.
14. Delafontaine P, Anwar A, Lou H, Ku L (1996) G-protein coupled and tyrosine kinase receptors: Evidence that activation of the insulin-like growth factor I receptor is required for thrombin-induced mitogenesis of rat aortic smooth muscle cells. J Clin Invest 97 : 139 145.
15. Dykxhoorn DM, Novina CD, Sharp PA (2003) Killing the messenger: Short RNAs that silence gene expression. Nat Rev Mol Cell Biol 4 : 457 467.
16. Ehsan A, Mann MJ, Dell'Acqua G, Dzau VJ (2001) Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg 121 : 714 722.
17. Ehsan A, Mann MJ, Dell'Acqua G, Tamura K, Braun-Dullaeus R, Dzau VJ (2002) Endothelial healing in vein grafts: Proliferative burst unimpaired by genetic therapy of neointimal disease. Circulation 105 : 1686 1692.
18. Fulton GJ, Davies MG, Barber L, Svendsen E, Hagen PO (1998) Locally applied antisense oligonucleotide to proliferating cell nuclear antigen inhibits intimal thickening in experimental vein grafts. Ann Vasc Surg 12 : 412 417.
19. George SJ, Angelini GD, Capogrossi MC, Baker AH (2001) Wild-type p53 gene transfer inhibits neointima formation in human saphenous vein by modulation of smooth muscle cell migration and induction of apoptosis. Gene Ther 8 : 668 676.
20. Goukassian DA, Kishore R, Krasinski K, Dolan C, Luedemann C, Yoon YS, Kearney M, Hanley A, Ma H, Asahara T, et al 2003) Engineering the response to vascular injury: Divergent effects of deregulated E2F1 expression on vascular smooth muscle cells and endothelial cells result in endothelial recovery and inhibition of neointimal growth. Circ Res 93 : 162 169.
21. Grube E, Felderhoff T, Fitzgerald P, Terashima M, Gerckens U, Orav E, Lorenz T, Iversen S (2001) Phase II trial of the E2F decoy in coronary bypass grafting. (Abstract), in American Heart Association Annual Meeting (Late Breaking Clinical Trials), Anaheim, CA.
22. Hart CE, Kraiss LW, Vergel S, Gilbertson D, Kenagy R, Kirkman T, Crandall DL, Tickle S, Finney H, Yarranton G, et al 1999) PDGFbeta receptor blockade inhibits intimal hyperplasia in the baboon. Circulation 99 : 564 569.
23. Kim S, Iwao H (2000) Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52 : 11 34.
24. Levin AAH, SP, Bennett CF, Cole DL, Hardee GE, Srivatsa GS (1999) Preclinical development of antisense therapeutics. In : Oxender DLP, L.E. ed. Novel therapeutics from modern biotechnology. Berlin, Springer-Verlag, pp. 131 163.
25. Mann MJ, Gibbons GH, Hutchinson H, Poston RS, Hoyt EG, Robbins RC, Dzau VJ (1999a) Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc Natl Acad Sc USA 96 : 6411 6416.
26. Mann MJ, Gibbons GH, Kernoff RS, Diet FP, Tsao PS, Cooke JP, Kaneda Y, Dzau VJ (1995) Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci USA 92 : 4502 4506.
27. Mann MJ, Gibbons GH, Tsao PS, von der Leyen HE, Cooke JP, Buitrago R, Kernoff R, Dzau VJ (1997) Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. J Clin Invest 99 : 1295 1301.
28. Mann MJ, Whittemore AD, Donaldson MC, Belkin M, Conte MS, Polak JF, Orav EJ, Ehsan A, Dell'Acqua G, Dzau VJ (1999b) Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial. Lancet 354 : 1493 1498.
29. Millette E, Rauch BH, Defawe O, Kenagy RD, Daum G, Clowes AW (2005) Platelet-derived growth factor-BB-induced human smooth muscle cell proliferation depends on basic FGF release and FGFR-1 activation. Circ Res 96 : 172 179.
30. Morishita R, Gibbons GH, Ellison KE, Nakajima M, von der Leyen H, Zhang L, Kaneda Y, Ogihara T, Dzau VJ (1993) Antisense oligonucleotides directed at cell cycle regulatory genes as strategy for restenosis therapy. Trans Assoc Am Phys 106 : 54 61.
31. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakama M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ (1995) A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 92 : 5855 5859.
32. Schwartz LB, Moawad J, Svensson EC, Tufts RL, Meyerson SL, Baunoch D, Leiden JM (1999) Adenoviral-mediated gene transfer of a constitutively active form of the retinoblastoma gene product attenuates neointimal thickening in experimental vein grafts. J Vasc Surg 29 : 874 881 discussion 882-873.
33. Spyridopoulos I, Principe N, Krasinski KL, Xu S, Kearney M, Magner M, Isner JM, Losordo DW (1998) Restoration of E2F expression rescues vascular endothelial cells from tumor necrosis factor-alpha-induced apoptosis. Circulation 98 : 2883 2890.
34. Stanelle J, Putzer BM (2006) E2F1-induced apoptosis: Turning killers into therapeutics. Trends Mol Med 12 : 177 185.
35. Stevaux O, Dyson NJ (2002) A revised picture of the E2F transcriptional network and RB function. Curr Opin Cell Biol 14 : 684 691.
36. Tomita N, Morishita R (2004) Antisense oligonucleotides as a powerful molecular strategy for gene therapy in cardiovascular diseases. Curr Pharm Des 10 : 797 803.
37. Trimarchi JM, Lees JA (2002) Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 3 : 11 20.